SLMP53-1 |
| Katalog-Nr.GC65284 |
SLMP53-1 ist ein Wildtyp- und mutanter p53-Reaktivator mit vielversprechender AntitumoraktivitÄt. SLMP53-1 vermittelt die Neuprogrammierung des Glukosestoffwechsels in Krebszellen. SLMP53-1 verringert die Angiogenese, verringert die Bildung von EndothelzellschlÄuchen und die Expressionsspiegel des vaskulÄren endothelialen Wachstumsfaktors (VEGF).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1643469-17-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
SLMP53-1 is a wild-type and mutant p53 reactivator with promising antitumor activity. SLMP53-1 mediates the reprograming of glucose metabolism in cancer cells. SLMP53-1 depletes angiogenesis, decreasing endothelial cell tube formation and vascular endothelial growth factor (VEGF) expression levels[1][2].
[1]. Gomes S, et al. SLMP53-2 Restores Wild-Type-Like Function to Mutant p53 through Hsp70: Promising Activity in Hepatocellular Carcinoma. Cancers (Basel). 2019 Aug 10;11(8):1151.
[2]. Ramos H, et al. SLMP53-1 Inhibits Tumor Cell Growth through Regulation of Glucose Metabolism and Angiogenesis in a P53-Dependent Manner. Int J Mol Sci. 2020 Jan 17;21(2):596.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *